Aethlon Subsidiary to Collaborate With University on Cancer Research

San Diego-based Aethlon Medical Inc., a company developing targeted therapeutic devices to address infectious diseases and cancer, announced that its majority-owned subsidiary Exosome Sciences Inc. has entered into a research collaboration with Thomas Jefferson University, which is in Philadelphia.

The goal of the collaboration is to advance a "liquid biopsy" that could improve the diagnoses and monitoring of head and neck cancer. In this regard, researchers will seek to determine whether exosome-based molecular signatures correlate with and predict patient responses to therapy.

Aethlon Medical’s lead product is the Aethlon Hemopurifier, a therapeutic device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences is a subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders.

 Additional stories from the San Diego Business Journal are available here. Sign up for their free daily email newsletter.

Contact Us